Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to HER2-positive Breast Cancer
Related studies linked through entity extraction aliases.
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
- Status
- UNKNOWN
- Phase
- PHASE2
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
- Status
- RECRUITING
- Phase
- PHASE2
Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
- Status
- COMPLETED
- Phase
- PHASE1
Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction
- Status
- RECRUITING
- Phase
- NA
PRE-I-SPY Phase I/Ib Oncology Platform Program
- Status
- RECRUITING
- Phase
- PHASE1
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
TRUDI: TDXD+Durva in HER2+/Low IBC
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
- Status
- RECRUITING
- Phase
- PHASE3
PIK3CA in HER2+ BC and pCR Trial
- Status
- UNKNOWN
- Phase
- NA
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Thero2-01S22 in HER2-positive Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE2